Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
A phase Ib trial study of trabectedin when prescribed in combination with durvalumab in locally advanced/unresectable soft-tissue sarcoma and ovarian carcinomas.
Ovarian Carcinoma|Soft Tissue Sarcoma
DRUG: Combination of trabectedin with durvalumab
Maximum tolerated dose (MTD) evaluated on the first cycle (D1 to D21) of Trabectedin when administered in association with Durvalumab, During the first cycle (21 days)
Recommended phase II dose (RP2D) of the association of Trabectedin and given in combination with Durvalumab, Throughout the treatment period, on average of 6 months|Dose Limiting Toxicities (DLT) of Trabectedin given in combination with Durvalumab, During the first cycle (21 days)]|Toxicity graded using the common toxicity criteria from the NCI v4.0, Throughout the treatment period, on average of 6 months|Preliminary signs of antitumor activity of Trabectedin given in combination with Durvalumab in terms of objective response (OR) under treatment defined as CR or PR as per RECIST 1.1, Throughout the treatment period, an average of 6 months|Preliminary signs of antitumor activity of Trabectedin given in combination with Durvalumab in terms of objective response (OR) at 6 months defined as CR or PR as per RECIST 1.1, 6 months|Preliminary signs of antitumor activity of Trabectedin given in combination with Durvalumab in terms of best overall response under treatment as per RECIST 1.1, Throughout the treatment period, an average of 6 months|Preliminary signs of antitumor activity of Trabectedin given in combination with Durvalumab in terms of 6-month non-progression (NP) defined as CR, PR, and SD as per RECIST 1.1, 6-months|Preliminary signs of antitumor activity of Trabectedin given in combination with Durvalumab in terms of 1-year progression-free survival (PFS) as per RECIST 1.1, 1 year|Preliminary signs of antitumor activity of Trabectedin given in combination with Durvalumab in terms of 1-year Overall Survival (OS) as per RECIST 1.1, 1-year|Predictive biomarkers analysis (blood cytokines levels, Day 1|Predictive biomarkers analysis (blood cytokines levels), Day 21|Predictive biomarkers analysis (circulating immune cells levels), Day 1|Predictive biomarkers analysis (circulating immune cells levels), Day 21|Number of participants with circulating DNA available (Identification and monitoring of mutations observed at the level of the circulating tumor cells (liquid biopsies concept)., Day 1 of each cycle (Each cycle is 21 days)]|Number of participants with exploratory biomarkers available (Markers analyzed for Hematoxylin and eosin staining (H&E) on tumor samples), Baseline|Number of participants with exploratory biomarkers available (Markers analyzed for Hematoxylin and eosin staining (H&E) on tumor samples).,, cycle 2 Day 8|Number of participants with exploratory biomarkers available (Markers analyzed for Immunohistochemistry (IHC) on tumor samples), Baseline|Number of participants with exploratory biomarkers available (Markers analyzed for Immunohistochemistry (IHC) on tumor samples.)., cycle 2 Day 8|Exploratory analysis of predictive signature in responders (genomics and transcriptomics analysis)., Identification of predictive signature in responders by sequencing tumor sample, Baseline|Exploratory analysis of predictive signature in responders (genomics and transcriptomics analysis)., Identification of predictive signature in responders by sequencing tumor sample, cycle 2 Day 8|Exploration of mechanisms of resistance in non-responders (genomics and transcriptomics analysis), Identification of predictive signature in responders by sequencing tumor sample, Baseline|Exploration of mechanisms of resistance in non-responders (genomics and transcriptomics analysis)., Identification of predictive signature in responders by sequencing tumor sample, cycle 2 Day 8
This is a multicenter, prospective phase Ib trial based on a dose escalation study design (3+3 traditional design) assessing three dose levels of Trabectedin given with durvalumab, followed by two expansion cohorts once the MTD is established.